Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2025 | RAISN: indocyanine green-guided lymph node dissection in testicular cancer

Yue Che • 13 Mar 2025
EAU 2025
Genitourinary Cancer Testicular Cancer
RAISN

Yue Che, MD, University Hospital of Duesseldorf, Düsseldorf, Germany, discusses the evolving role of retroperitoneal lymph node dissection and therapy de-escalation in testicular cancer. The RAISN study (NCT06133543) investigates the feasibility of indocyanine green (ICG)-guided sentinel lymph node biopsy to reduce the need for adjuvant chemotherapy in patients with stage I testicular cancer. Interim results suggest the procedure is technically feasible and well tolerated, with no complications or relapses reported so far. Further research is needed to assess long-term efficacy and sensitivity. This interview took place at the 2025 European Association of Urology (EAU) Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals